<DOC>
	<DOCNO>NCT02433119</DOCNO>
	<brief_summary>A multi-center , randomize , double-blind , phase IV clinical trial compare efficacy safety OROSARTAN® tablet 5/160mg versus CODIOVAN® tablet 160/12.5mg patient essential hypertension uncontrolled valsartan 160mg monotherapy</brief_summary>
	<brief_title>The Efficacy Safety OROSARTAN® Versus CODIOVAN® Patients With Essential Hypertension Uncontrolled With Monotherapy</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>19 age A patient diagnose essential hypertension screening ( Visit 1 ) A patient understood objective clinical trial give write informed consent voluntarily A patient severe hypertension ( MSSBP≥200mmHg MSDBP≥120mmHg ) Visit 1 A subject difference ( MSSBP≥20mmHg MSDBP≥10mmHg ) blood pressure right leave arm screen evaluation Medical history evidence secondary form hypertension A subject history hypersensitivity CCB ( Calcium Channel Blocker ) , ARB ( Angiotensin II Receptor Blocker ) sulfonamide</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>